Export 41 results:
[ Author
Filters: First Letter Of Last Name is V [Clear All Filters]
“Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT C”, J Clin Oncol, vol. 31, no. 13, pp. 1662-8, 2013.
, “Single Marker Associations of Cell Cycle Pathway Genes with Advanced AMD”, in Annual Meeting, Association for Research in Vision and Ophthalmology (ARVO), Fort Lauderdale, FL, 2007.
, “Association of 2-Year Progression Along the AREDS AMD Scale and Development of Late Age-Related Macular Degeneration or Loss of Visual Acuity: AREDS Report 22.”, JAMA Ophthalmol, 2020.
, “Evaluating the Validity of the Age-Related Eye Disease Study Grading Scale for Age-Related Macular Degeneration: AREDS2 Report 10.”, JAMA Ophthalmol, vol. 134, no. 9, pp. 1041-7, 2016.
, , “Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection”, J Pediatric, vol. 135, pp. 675-82, 1999.
, “Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume.”, AIDS, vol. 14, no. 3, pp. 251-61, 2000.
, “Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume”, AIDS Res HumRetroviruses, vol. 14, pp. 251-61, 2000.
, “Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection.”, J Pediatr, vol. 135, no. 6, pp. 675-82, 1999.
, “Clinical trials referral resource. Current clinical trials administering the antiangiogenesis agent SU5416”, Oncology, vol. 14, pp. 13121315-16
1321-23, 2000.
, “Clinical trials referral resource. Current clinical trials administering the antiangiogenesis agent SU5416.”, Oncology (Williston Park), vol. 14, no. 9, pp. 1312, 1315-6, 1321-3, 2000.
, “Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding.”, PLoS One, vol. 16, no. 11, p. e0259361, 2021.
, “Prevalence of persistent pain 3 to 5 years post primary root canal therapy and its impact on oral health-related quality of life: PEARL Network findings.”, J Endod, vol. 40, no. 12, pp. 1917-21, 2014.
, “Frontloading in the Real-world Leveraging Smartphone Technology to Examine Rate of Alcohol Consumption Effects on Subjective Responses in Heavy Drinkers”, in 45th Annual Speaker & Poster Abstracts of the Research Society on Alcoholism, Orlando, Florida, 2022.
, “A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS.”, J Acquir Immune Defic Syndr Hum Retrovirol, vol. 12, no. 5, pp. 462-9, 1996.
, “Treatments for hypersensitive noncarious cervical lesions: a Practitioners Engaged in Applied Research and Learning (PEARL) Network randomized clinical effectiveness study.”, J Am Dent Assoc, vol. 144, no. 5, pp. 495-506, 2013.
, “Treatments for Hypersensitive Noncarious Cervical Lesions: A Practitioners Engaged in Applied Research and Learning (PEARL) Network Randomized Clinical Effectiveness Study”, J Am Dent Assoc, vol. 144, pp. 495-506, 2013.
, “Optical Coherence Tomography Reflective Drusen Substructures Predict Progression to Geographic Atrophy in Age-related Macular Degeneration.”, Ophthalmology, vol. 123, no. 12, pp. 2554-2570, 2016.
, , “Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.”, PLoS One, vol. 5, no. 1, p. e8816, 2010.
, “Cellular and Humoral Immunogenicity of ADMVA, a Clade C/B MVA-Based HIV-1 Candidate Vaccine, in Healthy Volunteers”, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
, “In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.”, PLoS One, vol. 6, no. 5, p. e19252, 2011.
, “Phase 1 Safety and Immunogenicity Evaluation of ADVAX a Multigenic, DNA-Based Clade C/B’ HIV-1 Candidate Vaccine”, PLoS ONE, vol. 5, p. e8617, 2010.
, “Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 Clade B'/C Candidate Vaccine”, PLOS One, vol. 5, p. e8816, 2010.
, “Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.”, PLoS One, vol. 5, no. 1, p. e8617, 2010.
,